Show simple item record

dc.creatorDastiridou, A.en
dc.creatorKalogeropoulos, C.en
dc.creatorBrazitikos, P.en
dc.creatorSymeonidis, C.en
dc.creatorAndroudi, S.en
dc.date.accessioned2015-11-23T10:25:14Z
dc.date.available2015-11-23T10:25:14Z
dc.date.issued2012
dc.identifier10.1586/ecp.12.37
dc.identifier.issn1751-2433
dc.identifier.urihttp://hdl.handle.net/11615/26939
dc.description.abstractCurrent treatment guidelines for chronic ocular inflammatory disease recommend the use of steroid-sparing agents. The development of conventional immunomodulatory agents has largely changed the visual outcome in these patients. However, disease refractory to these treatment modalities has led to the use of new biologic-response modifiers, agents that target specific components of the pathogenetic process. The purpose of this review is to summarize the mechanism of action, experimental evidence, side effects and current experience with the use of rituximab, daclizumab, abatacept, anakinra and IFN-alpha in ocular inflammatory disease.en
dc.source.uri<Go to ISI>://WOS:000209294800018
dc.subjectabatacepten
dc.subjectanakinraen
dc.subjectautoimmuneen
dc.subjectbiologic response modifieren
dc.subjectdaclizumaben
dc.subjectimmunomodulationen
dc.subjectinterferonen
dc.subjectnoninfectious uveitisen
dc.subjectrituximaben
dc.subjectscleritisen
dc.subjectPharmacology & Pharmacyen
dc.titleNew biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatmenten
dc.typejournalArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record